Literature DB >> 28975642

Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains.

L Boyanova1, G Gergova1, R Markovska1, D Yordanov1, I Mitov1.   

Abstract

The aim of the study was to detect anti-Helicobacter pylori activity of seven Lactobacillus delbrueckii subsp. bulgaricus (GLB) strains by four cell-free supernatant (CFS) types. Activity of non-neutralized and non-heat-treated (CFSs1), non-neutralized and heat-treated (CFSs2), pH neutralized, catalase-treated and non-heat-treated (CFSs3), or neutralized, catalase- and heat-treated (CFSs4) CFSs against 18 H. pylori strains (11 of which with antibiotic resistance) was evaluated. All GLB strains produced bacteriocin-like inhibitory substances (BLISs), the neutralized CFSs of two GLB strains inhibited >81% of test strains and those of four GLB strains were active against >71% of antibiotic resistant strains. Two H. pylori strains were BLIS resistant. The heating did not reduce the CFS activity. Briefly, all GLB strains evaluated produced heat-stable BLISs, although GLB and H. pylori strain susceptibility patterns exhibited differences. Bacteriocin-like inhibitory substance activity can be an advantage for the probiotic choice for H. pylori infection control. SIGNIFICANCE AND IMPACT OF THE STUDY: In this study, anti-Helicobacter pylori activity of seven Lactobacillus delbrueckii subsp. bulgaricus (GLB) strains was evaluated by four cell-free supernatant (CFS) types. The GLB strains produced heat-stable bacteriocin-like inhibitory substances (BLISs) with a strong anti-H. pylori activity and some neutralized, catalase- and heat-treated CFSs inhibited >83% of the test strains. Bacteriocin-like inhibitory substance production of GLB strains can render them valuable probiotics in the control of H. pylori infection.
© 2017 The Society for Applied Microbiology.

Entities:  

Keywords:  zzm321990Helicobacterzzm321990; zzm321990Lactobacilluszzm321990; antibiotics; bacteriocins; probiotics

Mesh:

Substances:

Year:  2017        PMID: 28975642     DOI: 10.1111/lam.12807

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  11 in total

Review 1.  Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects.

Authors:  Denisse Bravo; Anilei Hoare; Cristopher Soto; Manuel A Valenzuela; Andrew Fg Quest
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 2.  Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.

Authors:  Elham Patrad; Solmaz Khalighfard; Taghi Amiriani; Vahid Khori; Ali Mohammad Alizadeh
Journal:  Cell Oncol (Dordr)       Date:  2022-09-23       Impact factor: 7.051

3.  Imbalance between peptidoglycan synthases and hydrolases regulated lysis of Lactobacillus bulgaricus in batch culture.

Authors:  Shiwei Chen; Yifan Wu; Haiyue Niu; Jialei Sun; Xue Han; Lanwei Zhang
Journal:  Arch Microbiol       Date:  2021-06-22       Impact factor: 2.552

Review 4.  A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins.

Authors:  Raffaela Pero; Mariarita Brancaccio; Sonia Laneri; Margherita-Gabriella De Biasi; Barbara Lombardo; Olga Scudiero
Journal:  Biomolecules       Date:  2019-06-18

5.  Effect of a Probiotic Mixture in Captive Cheetahs (Acinonyx Jubatus) with Gastrointestinal Symptoms-A Pilot Study.

Authors:  Sara Mangiaterra; Anne Schmidt-Küntzel; Laurie Marker; Alessandro Di Cerbo; Renato Piccinini; Davide Guadagnini; Maria Elena Turba; Sara Berardi; Livio Galosi; Silvia Preziuso; Matteo Cerquetella; Giacomo Rossi
Journal:  Animals (Basel)       Date:  2022-02-07       Impact factor: 2.752

Review 6.  The role of key gut microbial metabolites in the development and treatment of cancer.

Authors:  Kayla Jaye; Chun Guang Li; Dennis Chang; Deep Jyoti Bhuyan
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 7.  Helicobacter pylori Infection and Gastric Dysbiosis: Can Probiotics Administration Be Useful to Treat This Condition?

Authors:  Giovanni Bruno; Giulia Rocco; Piera Zaccari; Barbara Porowska; Maria Teresa Mascellino; Carola Severi
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-09-10       Impact factor: 2.471

Review 8.  Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.

Authors:  Jianfu Ji; Hong Yang
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

Review 9.  Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.

Authors:  Paula Roszczenko-Jasińska; Marta Ilona Wojtyś; Elżbieta K Jagusztyn-Krynicka
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-14       Impact factor: 4.813

Review 10.  Role of Gastric Microorganisms Other than Helicobacter pylori in the Development and Treatment of Gastric Diseases.

Authors:  Xiaoyan Duan; Ping Chen; Xiaoxia Xu; Meiling Han; Jianbo Li
Journal:  Biomed Res Int       Date:  2022-03-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.